Tyra Biosciences CFO acquires 951 shares

Tyra Biosciences’ CFO received 951 ESPP shares on September 15, 2026, bringing his direct holdings to 37,115 shares including RSUs.

Rhea-AI Filing Summary

Tyra Biosciences, Inc. (TYRA) reported that its Chief Financial Officer, Alan Fuhrman, acquired 951 shares of common stock on September 15, 2026 through a grant or award under the company’s 2021 Employee Stock Purchase Plan at $9.129 per share. Following this acquisition, Fuhrman directly holds 37,115 shares of common stock, which includes restricted stock units. No transactions in this filing were made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 951 shares

Grant/Award 1 txn

Insider Fuhrman Alan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	951	$9.129	$9K

Holdings After Transaction: Common Stock — 37,115 shares (Direct)

Footnotes (2)

1. F1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
2. F2. Includes restricted stock units.

Key Figures

Shares acquired: 951 shares Acquisition price per share: $9.129 per share Total direct holdings after transaction: 37,115 shares +1 more

4 metrics

Shares acquired 951 shares Grant or award to the Chief Financial Officer on September 15, 2026

Acquisition price per share $9.129 per share Value assigned to the 951 shares acquired on September 15, 2026

Total direct holdings after transaction 37,115 shares Chief Financial Officer’s direct holdings after the September 15, 2026 acquisition, including restricted stock units

Number of non-derivative transactions reported 1 transaction Single reported acquisition of common stock on September 15, 2026

Key Terms

2021 Employee Stock Purchase Plan, restricted stock units

2 terms

2021 Employee Stock Purchase Plan financial

"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."

restricted stock units financial

"Includes restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TYRA’s Chief Financial Officer report?

Alan Fuhrman, Chief Financial Officer, acquired 951 shares of Tyra Biosciences common stock on September 15, 2026 as a grant or award under the company’s 2021 Employee Stock Purchase Plan.

At what price were the ESPP shares for TYRA acquired by the CFO?

The 951 shares of Tyra Biosciences common stock acquired by the Chief Financial Officer were valued at a price of $9.129 per share in the reported transaction on September 15, 2026.

How many TYRA shares does the CFO hold after this Form 4 transaction?

After the September 15, 2026 acquisition, the Chief Financial Officer directly holds 37,115 shares of Tyra Biosciences common stock. This total includes restricted stock units as disclosed in the filing footnotes.

Was the TYRA CFO’s September 15, 2026 share acquisition under a Rule 10b5-1 plan?

No. The filing indicates that the September 15, 2026 acquisition of 951 shares by the Chief Financial Officer was not made under a Rule 10b5-1 trading plan, as the related checkbox is not selected.

How were the newly acquired TYRA shares obtained by the CFO?

The 951 newly acquired shares of Tyra Biosciences common stock were obtained under the company’s 2021 Employee Stock Purchase Plan, as stated in the filing’s footnotes for the September 15, 2026 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 07:25 PM Accepted by SEC EDGAR 09/17/2026 - 07:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fuhrman Alan

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		A(1)	V	951	A	$9.129	37,115(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

2. Includes restricted stock units.

	/s/ Ali D. Fawaz, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)